Clinical trial • Phase III • Other

Oxygen for Extremely preterm birth (gestational age 23+0/7–27+6/7 weeks) | Bronchopulmonary dysplasia | Retinopathy of prematurity | Necrotising enterocolitis | Neonatal death

Phase III trial of Oxygen for Extremely preterm birth (gestational age 23+0/7–27+6/7 weeks) | Bronchopulmonary dysplasia | Retinopathy of prematurity | Ne…

Overview

Trial Therapeutic Area
Other
Trial Disease
Extremely preterm birth (gestational age 23+0/7–27+6/7 weeks) | Bronchopulmonary dysplasia | Retinopathy of prematurity | Necrotising enterocolitis | Neonatal death
Trial Stage
Phase III
Drug Modality
Small molecule
Paediatric Trial
Yes

Key dates

Initial CTIS Submission Date
06-08-2024
First CTIS Authorization Date
12-08-2024

Trial design

Randomised, manual adjustments of fio2 only (standard care) compared to closed-loop automatic control of fio2 (fio2-c) Phase III trial across 23 sites in Germany.

Randomised
Yes
Comparator
Manual adjustments of FiO2 only (standard care) compared to closed-loop automatic control of FiO2 (FiO2-C)
Target Sample Size
865
Trial Duration For Participant
730

Eligibility

Recruits 865 paediatric patients.

Vulnerable Population
Preterm infants (neonates) are identified as a vulnerable population; informed consent is handled via subject information and informed consent forms for parents/legal guardians (documents listed: FiO2-C_Elterninformation_V4-3_20210608_clean_public and Einwilligungs-und-Datenschutzerklaerung_V4_3-1-20210608_clean_public). No assent process for participants is described in the available record.

Inclusion criteria

  • {"criterion_text":"- GA at birth 23+0/7 to 27+6/7 weeks"}

Exclusion criteria

  • {"criterion_text":"- Decision not to provide full life support / decision for palliative care only before study entry\n- Severe congenital abnormalities (particularly those affecting respiratory, cardiovascular, or gastrointestinal function or long-term neuro-cognitive development, whereas a patent ductus arteriosus or a PFO/ASDII is not considered a congenital anomaly in preterm infants)\n- Postnatal age >48h\n- Lack of device enabling closed-loop automatic control of FiO2 before randomization"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- The primary outcome I is a composite of any of the following: • Death • Severe retinopathy of prematurity (severe ROP, as defined in 7.3.1) • Chronic lung disease of prematurity (BPD, according to the physiological definition as defined in 7.3.2) • Necrotizing enterocolitis (NEC, as defined in 7.3.3) until discharge from hospital","definition_or_measurement_approach":"Composite event occurrence recorded until discharge from hospital; component definitions referenced to protocol sections 7.3.1 (severe ROP), 7.3.2 (physiological definition of BPD) and 7.3.3 (NEC)."}
  • {"endpoint_text":"- The primary outcome II is a composite of any of the following: • death or neurodevelopmental impairment (defined as at least one of the following components: motor disability (GMFCS 2-5), language or cognitive delay (language composite score < 85 or cognitive composite score < 85 on Bayley Scales of Infant Development, 3rd edition) or severe visual or hearing impairment (need for a hearing aid or cochlear implant)) at 24 months corrected age.","definition_or_measurement_approach":"Composite assessed at 24 months corrected age; neurodevelopmental impairment defined by motor disability (GMFCS 2-5), Bayley Scales of Infant Development (3rd ed.) language or cognitive composite scores <85, or severe visual/hearing impairment (need for hearing aid or cochlear implant)."}

Secondary endpoints

  • {"endpoint_text":"- Individual components of the primary outcome variables and developmental scores of the Bayley Scales of Infant Development (3rd edition)","definition_or_measurement_approach":"Assessment of the individual components of the composite endpoints and measurement of developmental outcomes using the Bayley Scales of Infant Development (3rd edition)."}

Recruitment

Planned Sample Size
865
Recruitment Window Months
92
Consent Approach
Informed consent obtained from parents/legal guardians as documented by the available subject information and informed consent forms (documents: FiO2-C_Elterninformation_V4-3_20210608_clean_public; Einwilligungs-und-Datenschutzerklaerung_V4_3-1-20210608_clean_public). No participant assent process or languages listed in the available record.

Geography

Total Number Of Sites
23
Total Number Of Participants
865

Germany

Earliest CTIS Part Ii Submission Date
06-08-2024
Latest Decision Or Authorization Date
06-08-2025
Processing Time Days
365
Number Of Sites
23
Number Of Participants
865

Sites

Site Name
HELIOS Klinikum Erfurt GmbH
Department Name
Neonatology
Principal Investigator Name
Hans-Joerg Bittrich
Principal Investigator Email
hans-joerg.bittrich@helios-kliniken.de
Contact Person Name
Hans-Joerg Bittrich
Site Name
Klinikum Der Landeshauptstadt Stuttgart gKAöR
Department Name
Neonatology
Principal Investigator Name
Patrick Neuberger
Principal Investigator Email
P.Neuberger@klinikum-stuttgart.de
Contact Person Name
Patrick Neuberger
Site Name
Klinikum St Marien Amberg
Department Name
Neonatology
Principal Investigator Name
Andreas Fiedler
Principal Investigator Email
fiedler.andreas@klinikum-amberg.de
Contact Person Name
Andreas Fiedler
Site Name
Barmherzige Brueder, Klinik Sankt Hedwig
Department Name
Neonatology
Principal Investigator Name
Jochen Kittel
Principal Investigator Email
jochen.kittel@barmherzige-regensburg.de
Contact Person Name
Jochen Kittel
Site Name
Muenchen Klinik gGmbH
Department Name
Neonatology
Principal Investigator Name
Marcus Krueger
Principal Investigator Email
marcus.krueger@klinikum-muenchen.de
Contact Person Name
Marcus Krueger
Site Name
Diakonissen-Stiftungs-Krankenhaus Speyer gGmbH
Department Name
Neonatology
Principal Investigator Name
Hans-Juergen Gausepohl
Principal Investigator Email
hans-juergen.gausepohl@diakonissen.de
Contact Person Name
Hans-Juergen Gausepohl
Site Name
Universitaetsklinikum Muenster AöR
Department Name
Neonatology
Principal Investigator Name
Julia Sandkoetter
Principal Investigator Email
sandkoj@uk.muenster.de
Contact Person Name
Julia Sandkoetter
Contact Person Email
sandkoj@uk.muenster.de
Site Name
Klinikum Esslingen GmbH
Department Name
Neonatology
Principal Investigator Name
Christian von Schnakenburg
Principal Investigator Email
c.schnakenburg@klinikum-esslingen.de
Contact Person Name
Christian von Schnakenburg
Site Name
Universitaetsklinikum Duesseldorf AöR
Department Name
Neonatology
Principal Investigator Name
Thomas Hoehn
Principal Investigator Email
thomas.hoehn@uni-duesseldorf.de
Contact Person Name
Thomas Hoehn
Site Name
Hannoversche Kinderheilanstalt
Department Name
Neonatology
Principal Investigator Name
Anna Koluch
Principal Investigator Email
koluch@hka.de
Contact Person Name
Anna Koluch
Contact Person Email
koluch@hka.de
Site Name
Kreuznacher Diakonie
Department Name
Neonatology
Principal Investigator Name
Edmondo Hammond
Principal Investigator Email
hammoned@kreuznacherdiakonie.de
Contact Person Name
Edmondo Hammond
Site Name
Universitaetsklinikum Tuebingen AöR
Department Name
Neonatology
Principal Investigator Name
Axel Franz
Principal Investigator Email
axel.franz@med.uni-tuebingen.de
Contact Person Name
Axel Franz
Site Name
Klinikum am Steinenberg
Department Name
Neonatology
Principal Investigator Name
Hans-Christoph Schneider
Principal Investigator Email
Schneider_H@klin-rt.de
Contact Person Name
Hans-Christoph Schneider
Contact Person Email
Schneider_H@klin-rt.de
Site Name
Universitaetsklinikum Ulm AöR
Department Name
Neonatology
Principal Investigator Name
Harald Ehrhardt
Principal Investigator Email
harald.ehrhardt@uniklinik-ulm.de
Contact Person Name
Harald Ehrhardt
Site Name
Rems-Murr-Kliniken gGmbH
Department Name
Neontology
Principal Investigator Name
Ulrich Bernbeck
Principal Investigator Email
ulrich.bernbeck@rems-murr-kliniken.de
Contact Person Name
Ulrich Bernbeck
Site Name
KJF Klinik Augsburg, Klinik für Kinder und Jugendliche
Department Name
Neonatology
Principal Investigator Name
Thomas Voelkl
Principal Investigator Email
Voelkl.Thomas@josefinum.de
Contact Person Name
Thomas Voelkl
Contact Person Email
Voelkl.Thomas@josefinum.de
Site Name
Gesundheit Nord gGmbH Klinikverbund Bremen
Department Name
Neonatology
Principal Investigator Name
Thorsten Koerner
Principal Investigator Email
Thorsten.Koerner@gesundheitnord.de
Contact Person Name
Thorsten Koerner
Site Name
Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR
Department Name
Neonatology
Principal Investigator Name
Barbara Seipolt
Principal Investigator Email
Barbara.Seipolt@uniklinikum-dresden.de
Contact Person Name
Barbara Seipolt
Site Name
Universitaetsklinikum Leipzig AöR
Department Name
Neonatology
Principal Investigator Name
Ulrich Thome
Principal Investigator Email
ulrich.thome@medizin.uni-leipzig.de
Contact Person Name
Ulrich Thome
Site Name
Medizinische Hochschule Hannover
Department Name
Neonatology
Principal Investigator Name
Bettina Bohnhorst
Principal Investigator Email
bohnhorst.bettina@mh-hannover.de
Contact Person Name
Bettina Bohnhorst
Site Name
Klinik Hallerwiese - Cnopfsche Kinderklinik
Department Name
Neonatology
Principal Investigator Name
Michael Schroth
Principal Investigator Email
Michael.Schroth@diakoneo.de
Contact Person Name
Michael Schroth
Contact Person Email
Michael.Schroth@diakoneo.de
Site Name
Universitaetsklinikum Freiburg
Department Name
Neonatology
Principal Investigator Name
Hans Fuchs
Principal Investigator Email
hans.fuchs@uniklinik-freiburg.de
Contact Person Name
Hans Fuchs
Site Name
Perinatalzentrum der LMU München
Department Name
Neonatologie
Principal Investigator Name
Andreas Flemmer
Principal Investigator Email
andreas.flemmer@med.uni-muenchen.de
Contact Person Name
Andreas Flemmer

Sponsor

Primary sponsor

Full Name
Universitaetsklinikum Tuebingen AöR
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Germany

Investigational products

Investigational Product Name
OXYGEN PH.EUR.
Active Substance
Oxygen
Modality
Small molecule
Routes Of Administration
Inhalation (INHALATION USE)
Route
Inhalation
Maximum Dose
100 % (V/V) percent volume/volume

Related trials

Other published trials that may interest you.